Skip to content
akaturk Academic measurement
Sign in Sign up

OpenAlex topic

Protein Degradation and Inhibitors

This page lists works and academicians tagged with an OpenAlex topic. It is not a YÖKSİS primary or secondary field.

OpenAlex 607 works 8 author topics

Works

607 works

  1. International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma 2014
    YÖKSİS SJR Q1 JCR Q1 OpenAlex top 1% OpenAlex 100.0%

    No abstract yet.

  2. The PI3K AKT mTOR interactive pathway 2015
    YÖKSİS SJR Q1 JCR Q2 OpenAlex top 10% OpenAlex 97.1%

    The phosphatidylinositol 3-kinase (PI3K)/AKT/mammalian target of the rapamycin (mTOR) signalling pathway is hyperactivated or altered in many cancer types and regulates a broad range of cellular processes including survival, proliferation, growth, metabolism, angiogenesis and metastasis. The PI3K/AKT/mTOR pathway is r…

  3. Exploiting Synthetic Lethality for the Therapy of ABC Diffuse Large B Cell Lymphoma 2012
    YÖKSİS SJR Q1 JCR Q1 OpenAlex top 1% OpenAlex 99.9%

    No abstract yet.

  4. Consensus recommendations for standard investigative workup: report of the International Myeloma Workshop Consensus Panel 3 2011
    YÖKSİS SJR Q1 JCR Q1 OpenAlex top 1% OpenAlex 99.7%

    A panel of members of the 2009 International Myeloma Workshop developed guidelines for standard investigative workup of patients with suspected multiple myeloma. Both serum and urine should be assessed for monoclonal protein. Measurement of monoclonal protein both by densitometer tracing and/by nephelometric quantitat…

  5. Atypical Teratoid/Rhabdoid Tumor of the Central Nervous System: A Highly Malignant Tumor of Infancy and Childhood Frequently Mistaken for Medulloblastoma 1998
    OpenAlex top 10% OpenAlex 94.3%

    Fifty-five patients with atypical teratoid/rhabdoid tumors of the central nervous system were studied to define the clinical and pathologic features of this newly described neoplasm. The lesion occurred primarily in children younger than 2 (mean age at diagnosis, 17 months). The neoplasms were located in the posterior…

  6. Combined inhibition of BET family proteins and histone deacetylases as a potential epigenetics-based therapy for pancreatic ductal adenocarcinoma 2015
    SJR Q1 JCR Q1 OpenAlex top 1% OpenAlex 99.6%

    No abstract yet.

  7. Pomalidomide, bortezomib, and dexamethasone for patients with relapsed or refractory multiple myeloma previously treated with lenalidomide (OPTIMISMM): a randomised, open-label, phase 3 trial 2019
    YÖKSİS SJR Q1 JCR Q1 OpenAlex top 1% OpenAlex 99.8%

    No abstract yet.

  8. Pomalidomide, bortezomib, and dexamethasone for patients with relapsed or refractory multiple myeloma previously treated with lenalidomide (OPTIMISMM): a randomised, open-label, phase 3 trial 2019
    YÖKSİS SJR Q1 JCR Q1 OpenAlex top 1% OpenAlex 99.8%

    No abstract yet.

  9. Community assessment to advance computational prediction of cancer drug combinations in a pharmacogenomic screen 2019
    OpenAlex top 1% OpenAlex 99.9%

    The effectiveness of most cancer targeted therapies is short-lived. Tumors often develop resistance that might be overcome with drug combinations. However, the number of possible combinations is vast, necessitating data-driven approaches to find optimal patient-specific treatments. Here we report AstraZeneca's large d…

  10. Natural history of relapsed myeloma, refractory to immunomodulatory drugs and proteasome inhibitors: a multicenter IMWG study 2017
    YÖKSİS SJR Q1 JCR Q1 OpenAlex top 1% OpenAlex 99.6%

    No abstract yet.

  11. Personalized therapy in multiple myeloma according to patient age and vulnerability: a report of the European Myeloma Network (EMN) 2011
    YÖKSİS SJR Q1 JCR Q1 OpenAlex top 1% OpenAlex 99.4%

    Most patients with newly diagnosed multiple myeloma (MM) are aged > 65 years with 30% aged > 75 years. Many elderly patients are also vulnerable because of comorbidities that complicate the management of MM. The prevalence of MM is expected to rise over time because of an aging population. Most elderly patients with M…

  12. Integrated genomic characterization of IDH1-mutant glioma malignant progression 2016
    YÖKSİS SJR Q1 JCR Q1 OpenAlex top 1% OpenAlex 99.4%

    No abstract yet.

Academicians

8 academicians